Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Green Website

Jeffrey E. Green, M.D.

Selected Publications
1)  Joshi B, Leland P, Calvo A, Montuenga L, Green J, Puri R.
Human Adrenomedullin Upregulates IL-13Rα2 Chain in Human Prostate Cancer in vitro and in vivo: a Novel Approach for Sensitizing Prostate Cancer to Receptor Directed Anti-Cancer Therapy.
Cancer Research. 2008. In Press. [Journal]
2)  Bennett C, Green J.
Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of pre-clinical models.
Breast Cancer Research. 2008. In Press. [Journal]
3)  Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D, Medina D, Tsimelzon A, Hilsenbeck S, Green JE, Michalowska AM, Rosen JM.
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.
Cancer Res. 68: 4674-82, 2008. [Journal]
4)  Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, Huh JI, Sharp R, Qiu TH, Anver MR, Merlino G, Dickson RB, Johnson MD, Green JE.
Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis.
Oncogene. 2008. [Journal]
5)  Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, Liu ZY, Costes SV, Cho EH, Lockett S, Khanna C, Chambers AF, Green JE.
Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.
Cancer Res. 68: 6241-50, 2008. [Journal]
6)  Ohta S, Lai EW, Morris JC, Pang AL, Watanabe M, Yazawa H, Zhang R, Green JE, Chan WY, Sirajuddin P, Taniguchi S, Powers JF, Tischler AS, Pacak K.
Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells.
Mol. Carcinog. 47: 245-51, 2008. [Journal]
7)  Huh JI, Qiu TH, Chandramouli GV, Charles R, Wiench M, Hager GL, Catena R, Calvo A, LaVallee TM, Desprez PY, Green JE.
2-methoxyestradiol induces mammary gland differentiation through amphiregulin-epithelial growth factor receptor-mediated signaling: molecular distinctions from the mammary gland of pregnant mice.
Endocrinology. 148: 1266-77, 2007. [Journal]
8)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007. [Journal]
9)  Datta S, Hoenerhoff MJ, Bommi P, Sainger R, Guo WJ, Dimri M, Band H, Band V, Green JE, Dimri GP.
Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways.
Cancer Res. 67: 10286-95, 2007. [Journal]
10)  Shoushtari AN, Michalowska AM, Green JE.
Comparing genetically engineered mouse mammary cancer models with human breast cancer by expression profiling.
Breast disease. 28: 39-51, 2007. [Journal]
11)  Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerhoff MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, Shih JH, Green JE.
Identification of an Integrated SV40 T/t-Antigen Cancer Signature in Aggressive Human Breast, Prostate, and Lung Carcinomas with Poor Prognosis.
Cancer Res. 67: 8065-8080, 2007. [Journal]
12)  Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T, Perou CM.
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.
Genome Biol. 8: R76, 2007. [Journal]
13)  Catena R, Muniz-Medina V, Moralejo B, Javierre B, Best CJ, Emmert-Buck MR, Green JE, Baker CC, Calvo A.
Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.
Int. J. Cancer. 120: 2096-109, 2007. [Journal]
14)  Hudson TS, Hartle DK, Hursting SD, Nunez NP, Wang TT, Young HA, Arany P, Green JE.
Inhibition of Prostate Cancer Growth by Muscadine Grape Skin Extract and Resveratrol through Distinct Mechanisms.
Cancer Res. 67: 8396-405, 2007. [Journal]
15)  Hoenerhoff M, Michalowska A, Qiu T, Green JE. Gavin G, eds.
A Bioinformatics Approach to the Analysis of Animal Models of Cancer. In: Bioinformatics in Cancer and Cancer Therapy. Volume .
2006. In Press. [Book Chapter]
16)  Huh JI, Calvo A, Charles R, Green JE.
Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with Id-1 expression.
Cancer Res. 66: 3495-503, 2006. [Journal]
17)  Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, Hedayat S, Christov KT, Ray VH, Unterman TG, Swanson SM.
Inhibition of estrogen independent mammary carcinogenesis by disruption of growth hormone signaling.
Carcinogenesis. 2006. [Journal]
18)  Oakes SR, Robertson FG, Kench JG, Gardiner-Garden M, Wand MP, Green JE, Ormandy CJ.
Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions.
Oncogene. 2006. [Journal]
19)  Lubet RA, Green J, Steele VE, You M.
potential use of transgenic mice in chemoprevention studies. In: Cancer Chemoprevention. Volume .
NJ: Humana Press; 2005. In Press. [Book Chapter]
20)  Kee K, Green JE. Teicher BA, eds.
Breast cancer: insights from DNA microarrays. In: Drug Resistance in Malignant Disease. Volume .
NJ: Humana Press; 2005. In Press. [Book Chapter]
21)  Hsieh CL, Xie Z, Liu ZY, Green JE, Martin WD, Datta MW, Yeung F, Pan D, Chung LW.
A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals.
J. Mol. Endocrinol. 35: 293-304, 2005. [Journal]
22)  Huang S, Li Y, Chen Y, Podsypanina K, Chamorro M, Olshen AB, Desai KV, Tann A, Petersen D, Green JE, Varmus HE.
Changes in gene expression during the development of mammary tumors in MMTV-Wnt-1 transgenic mice.
Genome Biol. 6: R84, 2005. [Journal]
23)  Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, Hedayat S, Christov KT, Unterman TG, Swanson SM.
Disruption of Growth Hormone Signaling Retards Early Stages of Prostate Carcinogenesis in the C3(1)/Tag Mouse.
Endocrinology. 2005. [Journal]
24)  Gonzalez-Moreno O, Calvo A, Joshi BH, Abasolo I, Leland P, Wang Z, Montuenga L, Puri RK, Green JE.
Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.
Int. J. Cancer. 114: 870-8, 2005. [Journal]
25)  Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Oncogene. 24: 790-800, 2005. [Journal]
26)  Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S.
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
Proc Natl Acad Sci U S A. 102: 3219-24, 2005. [Journal]
27)  Calvo A, Gonzalez-Moreno O, Yoon CY, Huh JI, Desai K, Nguyen QT, Green JE.
Prostate cancer and the genomic revolution: Advances using microarray analyses.
Mutat Res. 576: 66-79, 2005. [Journal]
28)  Green JE, Hudson T.
The promise of genetically engineered mice for cancer prevention studies.
Nat Rev Cancer. 5: 184-98, 2005. [Journal]
29)  Petersen D, Chandramouli GV, Geoghegan J, Hilburn J, Paarlberg J, Kim CH, Munroe D, Gangi L, Han J, Puri R, Staudt L, Weinstein J, Barrett JC, Green J, Kawasaki ES.
Three microarray platforms: an analysis of their concordance in profiling gene expression.
BMC Genomics. 6: 63, 2005. [Journal]
30)  Barkan D, Montagna C, Ried T, Green JE. Holland E, eds.
Mammary Gland Cancer. In: Mouse Models of Human Cancer. Volume .
NY: Wiley; 2004. p. 103-131 [Book Chapter]
31)  Green JE, Desai KV, Ye Y, Kavanaugh C, Calvo A, Huh JI.
Application of gene expression profiling for validating models of human breast cancer.
Toxicol Pathol. 32 Suppl 1: 84-9, 2004. [Journal]
32)  Shih JH, Michalowska AM, Dobbin K, Ye Y, Qiu TH, Green JE.
Effects of pooling mRNA in microarray class comparisons.
Bioinformatics. 2004. [Journal]
33)  Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S.
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.
Oncogene. 2004. [Journal]
34)  Kawakubo H, Carey JL, Brachtel E, Gupta V, Green JE, Walden PD, Maheswaran S.
Expression of the NF-kappaB-responsive gene BTG2 is aberrantly regulated in breast cancer.
Oncogene. 23: 8310-9, 2004. [Journal]
35)  Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE.
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
Mol Endocrinol. 18: 2895-907, 2004. [Journal]
36)  Desai KV, Michalowska AM, Kondaiah P, Ward JM, Shih JH, Green JE.
Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN-mediated apoptotic response specific to the rat ventral prostate.
Mol Endocrinol. 2004. [Journal]
37)  Green JE, eds.
Genomic Approaches to the Study of Breast Cancer.
Breast Disease. 19: 1-91, 2004. [Journal (Editor)]
38)  Green JE, Desai K, Ye Y, Kavanaugh C, Calvo A, Huh JI.
Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy.
Clin Cancer Res. 10: 385S-90S, 2004. [Journal]
39)  Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.
Cancer Res. 64: 5973-81, 2004. [Journal]
40)  Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET.
Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease.
Cancer Res. 64: 5973-81, 2004. [Journal]
41)  Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, Lee WH.
Identification of a novel putative non-selenocysteine containing phospholipid hydroperoxide glutathione peroxidase (NPGPx) essential for alleviating oxidative stress generated from polyunsaturated fatty acids in breast cancer cells.
J Biol Chem. 279: 43522-9, 2004. [Journal]
42)  Utomo A, Jiang X, Furuta S, Yun J, Levin DS, Wang YC, Desai KV, Green JE, Chen PL, Lee WH.
Identification of a Novel Putative Non-selenocysteine Containing Phospholipid Hydroperoxide Glutathione Peroxidase (NPGPx) Essential for Alleviating Oxidative Stress Generated from Polyunsaturated Fatty Acids in Breast Cancer Cells.
J Biol Chem. 279: 43522-9, 2004. [Journal]
43)  Ye Y, Qiu TH, Kavanaugh C, Green JE.
Molecular mechanisms of breast cancer progression: lessons from mouse mammary cancer models and gene expression profiling.
Breast Dis. 19: 69-82, 2004. [Journal]
44)  Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE, Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS.
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clin Cancer Res. 10: 327S-330S, 2004. [Journal]
45)  Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE.
VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Life Sci. 74: 1345-57, 2004. [Journal]
46)  Fargiano AA, Desai KV, Green JE.
Interrogating mouse mammary cancer models: insights from gene expression profiling.
J Mammary Gland Biol Neoplasia. 8: 321-34, 2003. [Journal]
47)  Robertson FG, Harris J, Naylor MJ, Oakes SR, Kindblom J, Dillner K, Wennbo H, Törnell J, Kelly PA, Green J, Ormandy CJ.
Prostate development and carcinogenesis in prolactin receptor knockout mice.
Endocrinology. 144: 3196-205, 2003. [Journal]
48)  Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K.
A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.
J. Biol. Chem. 276: 5992-9, 2001. [Journal]
49)  Gonzales-Moreno O, Calvo A, Joshi BH, Abasolo I, Wang A, Montuenga L, Puri RK, Green JE.
Gene expression profiling identifities IL-3 receptor alpha2 chani as a therapeutic target in prostate tumor cells over-expression adrenomedullin.
Int. J. Cancer. in press, . [Journal]
50)  Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, Philp D, Kleinman HK, Green JE.
Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through anti-angiogenic and non-antiangiogenic mechanisms.
Oncogene. in press., . [Journal]
51)  Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE.
Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
Proc Natl Acad Sci U S A. 99: 6967-72, 2002. [Journal]
52)  Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, Lubet R.
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Cancer Res. 61: 7449-55, 2001. [Journal]
53)  Calvo A, Feldman AL, Libutti SK, Green JE.
Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice.
Cancer Res. 62: 3934-8, 2002. [Journal]
54)  Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE.
Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.
Cancer Res. 62: 5325-35, 2002. [Journal]
55)  Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE.
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Carcinogenesis. 24: 453-9, 2003. [Journal]
56)  Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL.
Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.
Breast Cancer Res Treat. 77: 65-76, 2003. [Journal]
57)  Kaczmarczyk SJ, Green JE.
Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions.
Nucleic Acids Res. 31: e86, 2003. [Journal]
58)  Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR.
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis.
Diagn Mol Pathol. 12: 63-70, 2003. [Journal]
59)  Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, LeRoith D, Yakar S.
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors.
Cancer Res. 63: 4384-8, 2003. [Journal]
60)  Kavanaugh C, Green JE.
The use of genetically altered mice for breast cancer prevention studies.
J Nutr. 133: 2404S-2409S, 2003. [Journal]
61)  Desai KV, Kavanaugh CJ, Calvo A, Green JE.
Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
Endocr Relat Cancer. 9: 207-20, 2002. [Journal]
62)  Desai KV, Kavanaugh CJ, Calvo A, Green JE.
Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.
Endocr Relat Cancer. 9: 207-20, 2002. [Journal]
63)  Soares CR, Shibata MA, Green JE, Jorcyk CL.
Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.
Neoplasia. 4: 112-20, 2002. [Journal]
64)  Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE.
Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin.
Int J Cancer. 101: 224-34, 2002. [Journal]
65)  Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Senger DR.
Molecular profiling of angiogenesis markers.
Am J Pathol. 161: 35-41, 2002. [Journal]
66)  Kavanaugh CJ, Desai KV, Calvo A, Brown PH, Couldrey C, Lubet R, Green JE.
Pre-clinical applications of transgenic mouse mammary cancer models.
Transgenic Res. 11: 617-33, 2002. [Journal]
67)  Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, Lamph WW, Kuhn JG, Green JE, Brown PH.
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Cancer Epidemiol Biomarkers Prev. 11: 467-74, 2002. [Journal]
68)  Green JE, Cardiff R, Hennighausen L, Wakefield L, Wagner U, Lee E, Rosen J, Medina D, Nitkin A, Liu E.
Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM.
Transgenic Res. 11: 635-6, 2002. [Journal]
69)  Wubah JA, Fischer CM, Rolfzen LN, Khalili M, Kang J, Green JE, Bieberich CJ.
Ventral prostate predominant l, a novel mouse gene expressed exclusively in the prostate.
Prostate. 51: 21-9, 2002. [Journal]
70)  Kaczmarczyk SJ, Green JE.
A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression.
Nucleic Acids Res. 29: E56-6, 2001. [Journal]
71)  Wigginton JM, Park JW, Gruys ME, Young HA, Jorcyk CL, Back TC, Brunda MJ, Strieter RM, Ward J, Green JE, Wiltrout RH.
Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis.
J Immunol. 166: 1156-68, 2001. [Journal]
72)  Liu ML, Shibata MA, Von Lintig FC, Wang W, Cassenaer S, Boss GR, Green JE.
Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
Oncogene. 20: 2044-9, 2001. [Journal]
73)  Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE.
Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.
Cancer Gene Ther. 8: 23-35, 2001. [Journal]
74)  Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH.
9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.
Clin Cancer Res. 6: 3696-704, 2000. [Journal]
75)  Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S.
Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model.
Cancer Res. 60: 4362-5, 2000. [Journal]
76)  Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE.
Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
Cancer Res. 60: 6901-10, 2000. [Journal]
77)  Hahm KB, Im YH, Lee C, Parks WT, Bang YJ, Green JE, Kim SJ.
Loss of TGF-beta signaling contributes to autoimmune pancreatitis.
J Clin Invest. 105: 1057-65, 2000. [Journal]
78)  Couldrey C, Green JE.
Metastases: the glycan connection.
Breast Cancer Res. 2: 321-3, 2000. [Journal]
79)  Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C.
The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Oncogene. 19: 1020-7, 2000. [Journal]
80)  Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE.
The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting.
Oncogene. 19: 968-88, 2000. [Journal]

This page was last updated on 11/21/2008.